GlassScriptPhysician profile
Jorge Rivera-Jimenez
NPI 1902978059
$1,551.36
in general payments reported to CMS, 2019-2025
22 companies · $279 in 2025
The $279 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $72.18 · 2021: $230 · 2022: $320 · 2023: $205 · 2024: $314 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $381.17 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $163.34 | 2019-2024 | |
| Pfizer INC. | $163.26 | 2020-2024 | |
| Teleflex LLC | $139.44 | 2022 | |
| Merck Sharp & Dohme LLC | $137.36 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Alk-Abello, INC | $77.85 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Cranial Technologies, INC | $62.24 | 2023-2024 | Doc Band |
| Tris Pharma INC | $55.86 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $43.73 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $43.62 | 2025 | Relexxii |
| Ultragenyx Pharmaceutical INC. | $37.93 | 2021 | |
| Organon LLC | $31.12 | 2022 | |
| Sanofi Pasteur INC. | $31.12 | 2021-2024 | |
| Verrica Pharmaceuticals INC. | $26.29 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $24.95 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.79 | 2019 | |
| Mayne Pharma Commercial LLC | $19.92 | 2025 | |
| Glaxosmithkline, LLC. | $19.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.97 | 2024 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $18.68 | 2025 | Cotempla Xr-Odt |
| Phadia US INC. | $15.67 | 2023 | Immunocap |
| Genentech USA, INC. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Rivera-Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.